Oxford BioMedica (LSE:OXB) Long-Term Capital Lease Obligation : £69.27 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Long-Term Capital Lease Obligation?

Oxford BioMedica's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was £69.27 Mil.

Oxford BioMedica's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (£71.21 Mil) to Jun. 2023 (£71.05 Mil) and declined from Jun. 2023 (£71.05 Mil) to Dec. 2023 (£69.27 Mil).

Oxford BioMedica's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (£8.49 Mil) to Dec. 2022 (£71.21 Mil) but then declined from Dec. 2022 (£71.21 Mil) to Dec. 2023 (£69.27 Mil).

Oxford BioMedica Long-Term Capital Lease Obligation Historical Data

The historical data trend for Oxford BioMedica's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Long-Term Capital Lease Obligation Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

7.91

9.37

8.49

71.21

69.27

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															8.49	37.05	71.21	71.05	69.27

Oxford BioMedica (LSE:OXB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Oxford BioMedica Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines